摘要
目的观察阿托伐他汀对慢性心衰患者尿微量白蛋白(MAU)和高敏C反应蛋白(hsCRP)的影响,为防治慢性心衰早期肾损害提供临床依据。方法将120例慢性心衰患者随机分为对照组(n=60)和他汀组(n=60),对照组给予常规抗心衰药物治疗,他汀组在常规治疗基础上加用阿托伐他汀20mg/d;观察2组患者治疗3个月前后TG、TC、LDL-C、Scr、Bun、MAU、hsCRP值变化。结果 2组治疗前后以及两组治疗后比较,TG、Scr、Bun值均无显著性差异;他汀组治疗后与治疗前比较以及他汀组与对照组治疗后比较,TC、LDL-C、MAU、hsCRP值均显著降低(P<0.05);MAU、hsCRP相关性分析呈显著负相关(r=-0.58,P=0.04)。结论阿托伐他汀对慢性心衰早期肾损害有保护作用,他汀类抗炎作用是其内在机制之一。
Objectives To investigate the protective effect and possible mechanism of atorvastatin on early impairment of renal function in chronic heart failure（CHF）.Methods 120 CHF patients were divided randomly into statin group（n=60）and control group （n=60）.statin group received atorvastatin（20mg/d） on the basis of conventional treatment of control group.The levers of TG、 TC、LDL-C、Scr、Bun、MAU、hsCRP were detected before and after 3 months treatment.Results There were no significant differences in the levels of TG、Scr、Bun between the two groups before and after treatment. After treatment the levels of TC、 LDL-C、MAU、hsCRP in statin group were significantly lower than that of control and before treatment（P〈0.05）.MAU was negatively correlated with hsCRP（r=-0.58,P=0.04）.Conclusions atorvastatin can efficiently improve early impairment of renal function in CHF.The possible mechanism is anti-inflammatory of atorvastatin.
出处
《中外医疗》
2010年第13期23-24,27,共3页
China & Foreign Medical Treatment
